Target intelligence / Profile preview

BMI1 proto-oncogene, polycomb ring finger messenger RNA 3' untranslated region (BMI1 mRNA 3'UTR)

Target
BMI1 mRNA 3'UTR
Molecular classification
Messenger RNA, Untranslated region, RNA regulatory element
01

Overview

BMI1 (B lymphoma Mo-MLV insertion region 1) is a core component of the Polycomb Repressive Complex 1 (PRC1), essential for epigenetic silencing and the maintenance of somatic and cancer stem cells (Source: UniProt P35226). The 3' untranslated region (3'UTR) of the BMI1 mRNA serves as a critical regulatory hub, containing sequences that dictate mRNA stability and translation rates (Source: PubMed PMID 28819230). Overexpression of BMI1 is linked to poor prognosis in various malignancies, including glioblastoma and leukemia, where it promotes cell survival and chemoresistance (Source: PubMed PMID 31515464). Therapeutic targeting of the BMI1 mRNA 3'UTR involves small molecules, such as PTC596, which bind to the 3'UTR to selectively inhibit translation and reduce BMI1 protein levels (Source: PTC Therapeutics). This post-transcriptional modulation leads to the depletion of BMI1, subsequently inducing apoptosis and reducing the self-renewal capacity of cancer stem cells (Source: PubMed PMID 30217980). Clinical development of these inhibitors focuses on their potential to overcome resistance to standard-of-care treatments in aggressive tumors (Source: ClinicalTrials.gov NCT02404480).

Other names
B lymphoma Mo-MLV insertion region 1 homolog messenger RNA 3' untranslated regionRNF51 mRNA 3'UTRPCGF4 mRNA 3'UTRBMI1 3' untranslated region
02

Mechanism of action

Small molecule binding to the 3'UTR of BMI1 mRNA to selectively inhibit translation and promote transcript degradation, resulting in the depletion of BMI1 protein.

03

Biological functions

Post-transcriptional regulationTranslation regulationmRNA stability control
04

Disease associations

CancerGlioblastomaDiffuse intrinsic pontine gliomaAcute myeloid leukemiaOvarian cancer
05

Safety considerations

Hematological toxicityNeutropeniaThrombocytopeniaPotential impact on normal stem cell populations
06

Interacting drugs

PTC596

1 more in the full profile.

07

Biomarkers

BMI1 protein expressionCD133p16INK4aH2AK119ub

Beyond the preview

Go deeper on BMI1 proto-oncogene, polycomb ring finger messenger RNA 3' untranslated region (BMI1 mRNA 3'UTR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMI1 proto-oncogene, polycomb ring finger messenger RNA 3' untranslated region (BMI1 mRNA 3'UTR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call